April 01, 2016 BTG announces US launch of LC Bead LUMI™
London, UK, 01 April 2016
BTG announces US launch of LC Bead LUMI™, ground-breaking radiopaque embolic bead
First and only, commercially available, radiopaque embolic bead in the US has potential to revolutionize treatment of hypervascular tumors and arteriovenous malformations
BTG plc (LSE: BTG), a global specialist healthcare company, today announced the launch of LC Bead LUMI™ in the US, the first commercially available radiopaque embolic bead for the embolization of hypervascular tumors and arteriovenous malformations (AVMs). LC Bead LUMI™ is a next generation development of LC Bead®, the market leading embolic bead.
The unique visibility of LC Bead LUMI™ during and after embolization supports the optimization of patient treatment by enabling real-time visible confirmation of bead location during the procedure. This provides interventional radiologists more control, while at the same time facilitating discovery of regions of under-treatment, allowing precise evaluation of the completeness of tumor treatment and enhanced end-point determination, with long-lasting radiopacity to support follow-up management.
“The launch of LC Bead LUMI™ has the potential to be a real game-changer in the field of embolization,” commented Raj Narayanan, Associate Professor of Clinical Radiology at the University of Miami. “Not only does it provide doctors and patients with reassurance that the tumor has been treated in its entirety, but it allows interventional radiologists like me to refine treatment as we go, with the subsequent prospect of improved outcomes for patients.”
LC Bead LUMI™ has been developed on the same technology platform and to the same high standard as LC Bead®, building upon its market leading clinical performance.
“With the launch of LC Bead LUMI™, BTG is helping to ensure embolization technology achieves its full potential,” commented Ken Pugh, BTG Vice President, Commercial Development and Interventional Oncology Marketing, the Americas. “The potential benefits of LC Bead LUMI™ are significant - it represents a new level of control and offers the unique opportunity to individualize patient treatment in order to help doctors see more and treat smarter, while at the same time providing reassurance to patients that the treatment is getting to where it needs to be. At BTG, we’re passionate about the potential of LC Bead LUMI™ and the power of interventional oncology to improve human health.”
Today’s launch represents the first market commercialization for LC Bead LUMI™, with regulatory clearances and launches planned for additional radiopaque bead products worldwide.
Visit us at SIR 2016 in Vancouver, and learn more about LC Bead LUMI™ during our Symposium – AS WE “SEE” IT: LC BEAD LUMI™ CLINICAL EXPERIENCE FROM EARLY USERS (Tuesday 5th April, 12pm, Room 121/122).
About BTG Interventional Medicine
BTG Interventional Medicine is part of BTG plc, a growing international specialist healthcare company. As medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavors to do more than BTG Interventional Medicine to help doctors in their quest to see more, reach further and treat smarter. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots, and varicose veins. To learn more about BTG Interventional Medicine, please visit: btg-im.com.
About LC Bead LUMI™
LC Bead LUMI™ is the first commercially available radiopaque embolic bead cleared by the US Food & Drug Administration (FDA) for the embolization of hypervascular tumors and arteriovenous malformations (AVMs). LC Bead LUMI™ provides visible confirmation of bead location during the procedure. The lasting radiopacity of LC Bead LUMI™ means they will also be visible in follow-up scans. For instructions for use and important safety information, please visit: LCBeadLUMI.com
For further information contact:
Chris Sampson, Corporate Communications Director
+44 20 7575 1595; Mobile: +44 7773 251 178
+44 208 618 2755; Mobile: +44 7725 925 841
Media Liaison – US
+1 202 828 5073; Mobile: +1 202 577 5847